First trial tests immune drug and radiation for devastating brain spread
NCT ID NCT03719768
Summary
This early-stage study aimed to find a safe dose of a two-part treatment for patients with leptomeningeal disease, a serious condition where cancer spreads to the fluid around the brain and spine. Sixteen patients received the immunotherapy drug avelumab along with whole brain radiation therapy. The main goal was to check for serious side effects and see how the immune system in the spinal fluid responded to the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.